chartexchange

Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire Inc. | Nov 5, 2026 7:00 AM EST

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing

Read original article